2020 Guide to Patient Support Services


Celgene Corporation offers patient support services for patients receiving Celgene medications through the Celgene Patient Support program. This program offers eligible patients a range of support services to access Celgene’s oncology drugs, regardless of their insurance status.

The drugs covered under this program are listed in the Table and include Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension/albumin-bound), Idhifa (enasidenib), Inrebic (fedratinib), Istodax (romidepsin), Pomalyst (pomalidomide), Revlimid (lenalidomide), Thalomid (thalidomide), and Vidaza (azacitidine).


Celgene Patient Support services provide patients the following services:

  • A single specialist assigned to help patients in their geographic area
  • Assistance with understanding patient insurance coverage for Celgene medications
  • Information about financial assistance for the prescribed Celgene medication.

Celgene Patient Support services provide financial assistance options for patients with any insurance.

Celgene Commercial Co-pay Program

This program is available for eligible patients with commercial or private insurance (including healthcare exchanges). The program provides assistance to help patients meet their copay or coinsurance costs, and reduces the copay responsibility to $25 or less for the prescribed Celgene medication.

Celgene Patient Assistance Program

The Celgene Patient Assistance Program provides support for qualified patients who are uninsured or underinsured. Celgene medications may be available at no cost to patients who meet the insurance and financial criteria. Patients must meet specified financial and eligibility requirements to qualify for assistance under this program.

Independent Third-Party Organizations

For patients who are unable to afford their medication (including patients with Medicare, Medicaid, or other government-sponsored insurance), Celgene Patient Support can provide information about independent third-party organizations that may be able to help patients with the cost of deductibles, copayments, and coinsurance, as well as insurance premiums. Financial and medical eligibility requirements vary.

Transportation Assistance

Celgene Patient Support can provide information about financial assistance for transportation costs to and from medical appointments. Independent third-party organizations may be able to help patients with transportation costs, such as gasoline, parking, tolls, and taxi, bus, or train fare, to and from medical appointments. Financial and medical eligibility requirements vary.


Eligibility criteria for participation in the Celgene Commercial Co-pay Program include:

  • Commercial or private insurance that does not cover the full cost of the prescribed Celgene medication
  • Residence in the United States or a US territory
  • Patients with government healthcare insurance, including Medicaid, Medicare, Medigap, TriCare, and CHAMPVA, are not eligible
  • Other eligibility requirements and restrictions apply; full “terms and conditions” are available at CelgenePatientSupport.com.


Celgene Patient Support specialists are available to assist with each step in the insurance approval process for prescribed Celgene medications. Celgene cannot provide insurance advice or make insurance decisions. These specialists will help with the following steps.

Benefits Investigation

  • Initiate a benefits investigation to determine copayment and other out-of-pocket costs
  • Assess prior authorization or precertification requirements
  • Educate patients about insurance coverage or other programs for which they may qualify.

Prior Authorization/Precertification Assistance

  • Assist with the prior authorization or precertification process by providing the necessary forms for completion
  • Follow up with the insurance provider to determine the outcome
  • Celgene provides a facilitation service and will not provide any medical input into a prior authorization.

Appeals Assistance

  • Provide information about the appeals process after a denied prior authorization, precertification, and/or claim
  • Supply a checklist of the required documentation for submission to the insurance company
  • Submit the appeal to the insurance company at the request of the patient and follow up on the status until a decision is reached
  • Celgene provides a facilitation service and will not provide any medical input into an appeal.


  • Enroll online at CelgenePatientSupport.com
  • For more information about Celgene Patient Support, call 800-931-8691, Monday-Friday, 8 am-6 pm ET (translation services available)
  • E-mail or fax the enrollment form. Download the English or Spanish enrollment form at CelgenePatientSupport.com and return it by e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. or fax it to 800-822-2496.


Patient support programs

Abraxane (paclitaxel protein-bound particles) for injectable suspension
Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy; locally advanced or metastatic non–small-cell lung cancer, in combination with carboplatin; metastatic pancreatic cancer, in combination with gemcitabine
Patient support programs

Idhifa (enasidenib) tablets
Relapsed or refractory acute myeloid leukemia associated with IDH2 mutation
Patient support programs

Inrebic (fedratinib)
Intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis
Patient support programs

Istodax (romidepsin)
Cutaneous T-cell lymphoma after at least 1 systemic therapy; peripheral T-cell lymphoma after ≥1 therapies
Patient support program

Pomalyst (pomalidomide)
Multiple myeloma, in combination with dexamethasone, after at least 2 therapies, including lenalidomide and a proteasome inhibitor, in patients whose disease progressed during or within 60 days of completing the last therapy
Patient support programs

Revlimid (lenalidomide) capsules
Multiple myeloma, in combination with dexamethasone or as maintenance after autologous hematopoietic stem-cell transplant; transfusion-dependent anemia from low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q; mantle-cell lymphoma in patients whose disease relapsed or progressed after 2 therapies, including bortezomib; previously treated follicular lymphoma, in combination with rituximab-containing therapy; previously treated marginal-zone lymphoma, in combination with rituximab-containing therapy
Patient support programs

Thalomid (thalidomide)a
Multiple myeloma, in combination with dexamethasone
Patient support programs

Vidaza (azacitidine)a
Chronic myelomonocytic leukemia, a subtype of myelodysplastic syndrome
Patient support program

aThis drug is also approved for noncancer conditions.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: